Pharmacological Treatment of Social Anxiety Disorder

Masdrakis, Vasilios G.; Turic, Dragana; Baldwin, David S.

doi:10.1159/000351960

Cited by 4 publications

(3 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SAD is a risk factor for major depressive disorder and anxiety disorders such as generalized anxiety disorder (GAD) are frequently comorbid (9). Symptoms can be ameliorated, and function improved by a number of treatments including selective serotonin reuptake inhibitors (SSRIs) and other antidepressants, benzodiazepines, and pregabalin as well as cognitive and behavioral therapies (10). Each of these has limitations, most notably poor tolerance to sexual adverse effects associated with SSRIs and other antidepressants, and sedation/risk for tolerance and abuse with benzodiazepines.…”

Section: Introductionmentioning

confidence: 99%

The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study

Schmidt

Liebowitz

Stein

et al. 2020

Neuropsychopharmacol.

View full text Add to dashboard Cite

JNJ-42165279 is a selective inhibitor of fatty acid amide hydrolase (FAAH), the enzyme responsible for the degradation of fatty acid amides (FAA) including anandamide (AEA), palmitoylethanolamide (PEA), and N-oleoylethanolamide (OEA). We assessed the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of treatment with JNJ-42165279 in subjects with social anxiety disorder (SAD). This was a multicenter, double-blind, placebo-controlled study randomizing subjects to 12 weeks of treatment with either JNJ-42165279 (25 mg daily) or placebo (PBO). The primary endpoint was the change in the Liebowitz Social Anxiety Scale (LSAS) total score from baseline to end of study. Secondary endpoints included the Hamilton Anxiety Scale (HAM-A), Hamilton Depression Rating Scale (HDRS17), and the Clinical Global Impression-Improvement (CGI-I). Samples were collected for plasma concentration of AEA, PEA, OEA, and JNJ-42165279. A total of 149 subjects were enrolled with a mean baseline LSAS total score of 102.6 (SD 16.84). The mean change from baseline (SD) in LSAS total score at week 12 was numerically greater for JNJ-42165279: −29.4 (27.47) compared to PBO: −22.4 (23.57) but not significant. The percentage of subjects with ≥30% improvement from baseline in the LSAS total score was significantly higher for JNJ-42165279 (42.4%) compared to PBO (23.6%) (p value = 0.04). The percentage of subjects with a CGI-I score of much or very much improved was also significantly higher for JNJ-42165279 (44.1%) than for PBO (23.6%) (p value = 0.02). The drug was well tolerated. JNJ-42165279 appears to elicit an anxiolytic effect in subjects with SAD although trough concentrations with 25 mg once daily appeared to be insufficient to completely inhibit FAAH activity which may have led to suboptimal efficacy. ClinicalTrials.gov Identifier: NCT02432703.

show abstract

Section: Introductionmentioning

confidence: 99%

The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study

Schmidt

Liebowitz

Stein

et al. 2020

Neuropsychopharmacol.

View full text Add to dashboard Cite

show abstract

“…Os BZ não foram considerados medicamentos de primeira linha para o tratamento de TA. As pesquisas sugerem que os Inibidores Seletivos para Recaptação de Serotonina (os SSRIs) se mostram mais seguros e eficazes, especialmente em casos de utilização dos BZ por maior tempo 34,35,36,37,38 .…”

Section: Discussionunclassified

Eficácia dos benzodiazepínicos no tratamento de transtornos ansiosos: uma revisão de literatura

Ribeiro¹,

Brito²

2022

Rev. Med. (São Paulo)

View full text Add to dashboard Cite

Com o crescente índice de transtornos ansiosos na população mundial, cresce a necessidade de se investigar psicofármacos que possibilitem experiências de tratamento, segurança e sustentabilidade ao paciente. Dessa forma, o objetivo desta pesquisa é realizar uma revisão sistemática metodológica acerca da eficácia dos benzodiazepínicos (BZ) para o tratamento de transtornos ansiosos (TA). Os estudos foram pesquisados nas bases de dados da PubMed e ScienceDirect, a partir dos descritores: “benzodiazepines” e “anxiety disorder”. Será utilizado o operador booleano “AND”. Foram revisados 27 artigos científicos, com amostra total de 120.418 pacientes de estudos publicados entre os anos de 2011 e 2021, sendo 15 revisões sistemáticas, 5 revisões sistemáticas com meta-análise, 2 meta-análises, 1 revisão sistemática com estudo original, 1 ensaio clínico, 1 ensaio clínico com caso controle, 1 ensaio clínico com estudo prospectivo e 1 estudo duplo cego com ensaio clínico utilizando placebo. Percebeu-se que os BZ se mostraram efetivos no tratamento de transtornos ansiosos (ansiedade generalizada e fobia social), mas inviável em termos de qualidade e seguridade em relação ao seu potencial de dependência a longo prazo. Novos medicamentos foram considerados como possível substituição do BZ para os TA. Novos estudos considerando outros transtornos ansiosos são necessários, além dos que foram abordados nesta pesquisa.

show abstract

“…Effective treatment of social anxiety disorder (SAD) includes CBT and a spectrum of medications including some antidepressants, BDZs and anticonvulsants [71]. Many trials have been conducted with BDZs in the treatment of SAD.…”

Section: Social Anxiety Disordermentioning

confidence: 99%

Benzodiazepines and Anxiety Disorders: From Laboratory to Clinic

Samardžić¹,

Štrac²

2016

New Developments in Anxiety Disorders

View full text Add to dashboard Cite

Abstract"enzodiazepines "DZs , which are among the most wideρy prescribed drugs in current psychiatric practice, act as positive moduρators of G"""ergic neurotransmission. They are used to treat a wide range of disorders, from anxiety, afective disorders and insomnia to epiρepsy, aρcohoρ withdrawaρ and muscρe spasms. However, the deveρop-ment of toρerance and dependence after ρong-term "DZ treatment, as weρρ as the abuse potentiaρ, ρimit their use. "ρthough some other cρasses of drugs are currentρy considered as a beter choice for ρong-term treatment, "DZs to date stiρρ remain indispensabρe drugs. They are wideρy prescribed for anxiety disorders, with high ρeveρs of evidence existing for the short-term "DZ use in panic disorder and generaρized anxiety disorder, intermediate for sociaρ anxiety and poor in post-traumatic stress disorder and obsessivecompuρsive disorder. Future studies are intending to deveρop the new seρective drugs that act via "DZ receptors, but with noveρ, narrow proiρe of action. Furthermore, the research on aρternative therapeutic approaches of psychiatric disorders has shifted the focus onto therapeutic potentiaρ of naturaρ "DZ ρigands.

show abstract

Pharmacological Treatment of Social Anxiety Disorder

Cited by 4 publications

References 76 publications

The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study

The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study

Eficácia dos benzodiazepínicos no tratamento de transtornos ansiosos: uma revisão de literatura

Benzodiazepines and Anxiety Disorders: From Laboratory to Clinic

Contact Info

Product

Resources

About